2. Search Result
Search Result
Results for "

oral+administration

" in MedChemExpress (MCE) Product Catalog:

90

Inhibitors & Agonists

2

Biochemical Assay Reagents

9

Natural
Products

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100897
    Sulodexide

    		Thrombin Cardiovascular Disease
    Sulodexide is a mixture of glycosaminoglycans available in soft capsule form for oral administration. It is composed of low molecular weight heparin (80%) and dermatan sulfate (20%). Sulodexide exhibits antithrombotic activity through interaction with antithrombin III (AT III) and heparin cofactor II (HC II), and inhibition of thrombin formation. Sulodexide exhibits profibrinolytic activity through release of tissue plasminogen activator (tPA). Sulodexide exhibits endothelial protective and anti-inflammatory effect, ameliorates chronic venous disease . Sulodexide is a glycosaminoglycan mixture available in soft gelatin capsule form for oral administration.
    Sulodexide
  • HY-N6641
    Monascin
    2 Publications Verification

    		 Keap1-Nrf2 PPAR Inflammation/Immunology Cancer
    Monascin is a kind of azaphilonoid pigments extracted from Monascus pilosus-fermented rice (red-mold rice). Monascin also exhibits anti-tumor-initiating activity and anti-inflammatory activity with oral administration. Monascin inhibits the activation of NOR 1 (an NO donor). Monascin is a Nrf2 activator and PPARγ agonist .
    Monascin
  • HY-16100
    BI 99179
    3 Publications Verification

    		 Fatty Acid Synthase (FASN) Metabolic Disease Cancer
    BI 99179, a chemical probe, is a potent and selective type I fatty acid synthase (FAS) inhibitor with an IC50 of 79 nM. BI 99179 is a tool compound suitable for the in vivo validation of FAS as a target for lipid metabolism related diseases. BI 99179 exhibits significant exposure (both peripheral and central) upon oral administration in rats .
    BI 99179
  • HY-118189
    Misoprostol acid
    1 Publications Verification

    		 Prostaglandin Receptor Inflammation/Immunology
    Misoprostol acid is an active metabolite of Misoprostol. Misoprostol is a synthetic analogue of prostaglandin E1 (PGE1), extensively absorbed, and undergoes rapid de-esterification to Misoprostol acid in the gastrointestinal tract after oral administration. Misoprostol can be used for non-steroidal anti-inflammatory drug-induced (NSAID) gastric ulcers . Misoprostol is an oral agent used to induce labor .
    Misoprostol acid
  • HY-100634
    4-Hydroxypropranolol hydrochloride

    (±)-4-hydroxy Propranolol hydrochloride

    		 Adrenergic Receptor Cardiovascular Disease
    4-Hydroxypropranolol hydrochloride is a non-cardiac selective β-adrenergic receptor antagonist and a metabolite produced after oral administration of Propranolol (HY-B0573B). 4-Hydroxypropranolol hydrochloride also acts as a membrane stabilizer and possesses intrinsic sympathomimetic inhibitory activity. 4-Hydroxypropranolol hydrochloride blocks β-adrenergic receptors to antagonize the effects of catecholamines, acts as a partial β-adrenergic receptor agonist, and induces membrane stabilization. 4-Hydroxypropranolol hydrochloride alters heart rate, left ventricular contractility, and atrioventricular conduction time. 4-Hydroxypropranolol hydrochloride can be used in research related to cardiovascular and cerebrovascular diseases .
    4-Hydroxypropranolol hydrochloride
  • HY-Y0850U3
    PVA (Mw 125000, 98-99% hydrolyzed, ~2800 polymerization)

    Polyvinyl alcohol (Mw 125000, 98-99% hydrolyzed, ~2800 polymerization); Poly(Ethenol) (Mw 125000, 98-99% hydrolyzed, ~2800 polymerization)

    		 Biochemical Assay Reagents Others
    PVA (Polyvinyl alcohol) (Mw 125000, 98-99% hydrolyzed, ~2800 polymerization) is a water-soluble, biodegradable, biocompatible and non-immunogenic polymer. PVA (Mw 125000, 98-99% hydrolyzed, ~2800 polymerization) causes no irritation to rabbit eyes, no skin sensitization in guinea pigs, promotes the proliferation of human skin keratinocytes, and reduces the loss of corneal endothelial cells. The LD50 of PVA (Mw 125000, 98-99% hydrolyzed, ~2800 polymerization) in rats and dogs is greater than 10 g/kg. PVA (Mw 125000, 98-99% hydrolyzed, ~2800 polymerization) is hardly absorbed by the digestive system, causes no adverse effects upon long-term oral administration, and shows no mutagenicity or carcinogenicity. However, repeated intravenous or portal vein injection of PVA (Mw 125000, 98-99% hydrolyzed, ~2800 polymerization) may induce pathological changes such as glomerular lesions, anemia, hypertension or liver fibrosis in rats or dogs. Crosslinked nanofibers prepared by modifying PVA (Mw 125000, 98-99% hydrolyzed, ~2800 polymerization) can be used in studies related to wound dressings and other applications .
    PVA (Mw 125000, 98-99% hydrolyzed, ~2800 polymerization)
  • HY-164782
    PT3

    		HDAC Neurological Disease Metabolic Disease Cancer
    PT3 is a selective inhibitor of HDAC3 with an IC50 value of 0.25 μM. PT3 exhibits good brain penetration ability and bioavailability upon oral administration. PT3 can be used in the research of Alzheimer’s disease .
    PT3
  • HY-W013762
    Tributyl citrate

    		Environmental Pollutants Biochemical Assay Reagents Others
    Tributyl citrate is a low-toxicity and orally active citrate ester with no genotoxicity or skin sensitizing activity. Tributyl citrate also acts as a plasticizer, solvent, FDA-approved indirect food additive, and topical anesthetic, among other uses. Tributyl citrate induces a needle-prick insensitivity response that lasts for more than 2 hours, and a 5% suspension of it temporarily eliminates the corneal reflex in rabbits. Tributyl citrate causes no significant systemic toxicity in rats and cats at most tested doses, and only may cause growth retardation and gastrointestinal reactions such as diarrhea and nausea at high doses or with repeated oral administration .
    Tributyl citrate
  • HY-N0856
    Alisol C 23-acetate

    23-O-Acetylalisol C; Alisol C monoacetate

    		 Others Cardiovascular Disease
    Alisol C 23-acetate, a natural product extracted from Alisma orinentale, can significantly and strongly inhibit DTH response after oral administration.
    Alisol C 23-acetate
  • HY-W011309
    1-O-Hexadecylglycerol

    1-O-HDG; HXDG

    		 PPAR PGE synthase Inflammation/Immunology
    1-O-Hexadecylglycerol can up-regulate PPAR-γ expression, inhibit pGE2, and exhibit anti-inflammatory properties . 1-O-Hexadecylglycerol is effective in oral administration .
    1-O-Hexadecylglycerol
  • HY-A0234
    Stepronin
    2 Publications Verification

    Prostenoglycine; TTPG; Tiase

    		 Chloride Channel Endocrinology
    Stepronin (Prostenoglycine) is an orally active expectorant (inhalation administration is preferable to oral administration). Stepronin inhibits airway secretion in vitro by reducing Cl - secretion from epithelial cells and mucus glycoprotein secretion from submucosal glands .
    Stepronin
  • HY-108288
    Sulbactam pivoxil

    Pivsulbactam; CP 47904

    		 Beta-lactamase Antibiotic Bacterial Infection
    Sulbactam pivoxil (Pivsulbactam) is a prodrug of Sulbactam (HY-B0334) with oral activity. Sulbactam is a β-lactamase inhibitor with antibacterial activity. Sulbactam pivoxil is better absorbed than Sulbactam and results in higher serum levels after oral administration .
    Sulbactam pivoxil
  • HY-14826
    Tilivapram

    AVE8112

    		 Phosphodiesterase (PDE) Neurological Disease
    Tilivapram (AVE8112) is an orally active PDE4 inhibitor with procognitive effects. Tilivapram exhibits in vivo efficacy and improves processing speed and psychomotor speed. Oral administration of tilivapram may induce dose-related adverse reactions such as nausea and dizziness, but transdermal delivery enables slow, controlled elevation of plasma concentrations, thereby significantly reducing gastrointestinal discomfort and dizziness. Tilivapram is applicable to research related to neuropsychiatric disorders .
    Tilivapram
  • HY-N2620
    Rutaevin

    		Cytochrome P450 Infection
    Rutaevin is an antifungal toxin and CYP3A4 inactivator. Rutaevin requires NADPH-dependent bioactivation to generate cis-but-2-ene-1,4-dial, which then covalently modifies and mechanism-based inactivates human CYP3A4 (IC50=4.48 μM, Ki=15.98 μM), and interacts with substances such as glutathione. Rutaevin disrupts the cellular structure of Sirococcus conigenus, accumulates linearly in resistant larch after pathogen exposure, and induces liver toxicity in mice via oral administration. Rutaevin can be applied to research in fields related to larch shoot blight and other associated areas .
    Rutaevin
  • HY-N10225
    Thielavin A

    		Prostaglandin Receptor Cardiovascular Disease Endocrinology
    Thielavin A is an inhibitor of prostaglandin biosynthesis produced by Thielavia terricola. Thielavin A specifically inhibits the conversion of arachidonic acid into prostaglandin H2. Thielavin A has no anti-inflammatory activity on intravenous injection or on oral administration .
    Thielavin A
  • HY-100085
    21-Desacetyldeflazacort

    21-desDFZ

    		 Drug Metabolite Inflammation/Immunology
    21-Desacetyldeflazacort (21-desDFZ) is the active metabolite of Deflazacort (HY-13609). Deflazacort is an anti-inflammatory and immunosuppressant. Deflazacort is an inactive pro-drug which can be rapidly converted by esterases to the active metabolite 21-desacetyldeflazacort after oral administration .
    21-Desacetyldeflazacort
  • HY-167840
    IMMH-010 maleate

    		PD-1/PD-L1 Neurological Disease Cancer
    IMMH-010 maleate is a prodrug that serves as a novel PD-L1 inhibitor, exhibiting potential antitumor activity for the treatment of neurological disorders and advanced malignant solid tumors. IMMH-010 maleate is rapidly converted to its active form, YPD-29B, following oral administration. IMMH-010 maleate is poised for advancing research in the field of PD-L1 inhibitors and related therapeutic applications.
    IMMH-010 maleate
  • HY-101122
    LX2761

    		SGLT GLP Receptor Metabolic Disease
    LX2761 is an orally active, dual SGLT1/SGLT2 inhibitor with IC50 values of 2.2 nM and 2.7 nM against human SGLT1 and SGLT2, respectively. LX2761 locks human SGLT1 in an outward-open conformation and blocks its putative water permeation pathway. After oral administration, LX2761 is confined exclusively to the intestinal lumen, delays intestinal glucose absorption, regulates intestinal glucose metabolism, increases cecal glucose levels, reduces cecal pH, improves glycemic control and elevates plasma total GLP-1 levels. However, LX2761 induces diarrhea in a dose-dependent manner. LX2761 can be used in diabetes-related research .
    LX2761
  • HY-W276164
    Sodium octadecyl sulfate

    Sodium stearyl sulfate

    		 Biochemical Assay Reagents Others
    Sodium octadecyl sulfate (Sodium stearyl sulfate) is a long-chain alkyl sodium sulfate that functions as an emulsifier, crosslinking agent, and regulator. Sodium octadecyl sulfate has high safety, with a LD50 greater than 3.00 Gm./Kg for both intraperitoneal injection in mice and oral administration in rats. Sodium octadecyl sulfate enhances continuous contraction of the gastrocnemius muscle in frogs and boosts intestinal smooth muscle activity in albino rats. However, Sodium octadecyl sulfate exerts no significant effect on isolated tortoise myocardium and does not alter the conduction function of frog sciatic nerves. Sodium octadecyl sulfate can also be used to coat the surface of starch aggregates, promote crosslinking and increase aggregate size through hydrophobic and electrostatic interactions, and further form a coexistent B-V type crystalline structure with acid-hydrolyzed gelatinized starch, thereby effectively modifying the structure and surface properties of high-starch systems .
    Sodium octadecyl sulfate
  • HY-145461
    Hydroxy lenalidomide

    5-Hydroxy lenalidomide

    		 Drug Metabolite Others
    Hydroxy lenalidomide (5-Hydroxy lenalidomide) is a metabolite of lenalidomide that is present as a minor component in plasma and excreta, accounting for less than 5% of the total radioactivity, following oral administration of lenalidomide in healthy male subjects.
    Hydroxy lenalidomide
  • HY-N4173
    8-Oxoepiberberine

    		Drug Metabolite Metabolic Disease
    8-Oxoepiberberine is an alkaloid metabolite in the plasma after oral administration of Zuojin formula, a traditional chinese medicine used to treat gastrointestinal disease .
    8-Oxoepiberberine
  • HY-118426
    (Rac)-Tipifarnib

    (Rac)-IND 58359; (Rac)-R115777

    		 Farnesyl Transferase Ras Cancer
    (Rac)-Tipifarnib ((Rac)-IND 58359; (Rac)-R115777) is a potent farnesyl protein transferase inhibitor that specifically targets the pro-tailation process of Ras proteins. (Rac)-Tipifarnib showed significant in vivo antitumor effects after oral administration to mice .
    (Rac)-Tipifarnib
  • HY-U00122
    Antiulcer Agent 1

    		Drug Derivative Inflammation/Immunology
    Antiulcer Agent 1 is a 2-(3,4-dimethoxyphenyl)ethylamine derivative for oral administration at an exploratory stage of new agent development.
    Antiulcer Agent 1
  • HY-N14880
    Oudenone

    		Antibiotic Bacterial Infection Cardiovascular Disease
    Oudenone is an oxygen-containing heterocyclic antibiotic. Oudenone has weak antibacterial and fungal activity. Oudenone has antihypertensive effect on spontaneous hypertension in rats by intraperitoneal injection or oral administration .
    Oudenone
  • HY-123186
    MB-11362

    RG-7348

    		 HCV Infection
    MB-11362 is an orally active, selective HCV NS5B polymerase inhibitor and 4′-azidouridine triphosphate prodrug. MB-11362 can be converted to 4′-azidouridine triphosphate after oral administration. MB-11362 can be used in the research of HCV infection .
    MB-11362
  • HY-105215
    FK888

    		Neurokinin Receptor Inflammation/Immunology
    FK888 is a potent, selective, and high affinity dipeptide NK1 receptor antagonist. FK888 displaces [3H]-SP binding with a Ki value of 0.69 nM and 0.45 microM. FK888 also inhibits SP-induced airway oedema in guinea-pig after both intravenous and oral administration .
    FK888
  • HY-159489
    SDUY038

    		SHP2 Cancer
    SDUY038 is a SHP2 allosteric inhibitor, with an IC50 of 1.2 μM and KD of 0.29 μM, respectively. SDUY038 exhibits pan-antitumor activity (IC50 = 7-24 μM) by suppressing pERK expression. SDUY038 exhibits t1/2 of 3.95 h by oral administration .
    SDUY038
  • HY-12096
    WAY-207024

    		GnRH Receptor Endocrinology
    WAY-207024 is an orally active gonadotropin releasing hormone receptor (GnRH-R) antagonist (human GnRH: IC50 of 12 nM, rat GnRH: IC50 of 71 nM). WAY-207024 inhibits rat LH release with an IC50 of 350 nM. WAY-207024 lowers rat plasma leuteinizing hormone (LH) levels after oral administration .
    WAY-207024
  • HY-111073
    Bentysrepinine

    Y101

    		 HBV Infection Inflammation/Immunology
    Bentysrepinine (Y101) is an orally active HBV inhibitor with anti-hepatitis B virus infection activity. Bentysrepinine exhibits favorable pharmacokinetic characteristics, with absolute bioavailability of 44.9%, 43.1%, and 19.2% in rats, dogs, and monkeys, respectively, and it does not accumulate in monkeys after 90 days of oral administration. Bentysrepinine is under research in the antiviral and hepatitis fields .
    Bentysrepinine
  • HY-108288R
    Sulbactam pivoxil (Standard)

    Pivsulbactam (Standard); CP 47904 (Standard)

    		 Beta-lactamase Reference Standards Antibiotic Bacterial Infection
    Sulbactam pivoxil (Standard) (Pivsulbactam (Standard)) is the analytical standard of Sulbactam pivoxil (HY-108288). This product is intended for research and analytical applications. Sulbactam pivoxil (Pivsulbactam) is a prodrug of Sulbactam (HY-B0334) with oral activity. Sulbactam is a β-lactamase inhibitor with antibacterial activity. Sulbactam pivoxil is better absorbed than Sulbactam and results in higher serum levels after oral administration .
    Sulbactam pivoxil (Standard)
  • HY-107129
    MK-3577

    		GCGR Metabolic Disease
    MK-3577 is an orally effective glucagon receptor (GCGR) antagonist that reduces hepatic glucose production and lowers blood glucose levels by blocking glucagon receptors on target organs, primarily the liver. Pharmacokinetic analysis in domestic cats indicates that MK-3577 reaches peak levels 3 to 4 hours after oral administration, with a half-life of approximately 15 hours. MK-3577 can be used in diabetes research .
    MK-3577
  • HY-129756
    Thioacetanilide

    N-Phenylthioacetamide

    		 Biochemical Assay Reagents Metabolic Disease
    Thioacetanilide (N-Phenylthioacetamide) is a sulfur-containing thioamide derivative of acetanilide. Thioacetanilide displays a solvent‑dependent Z/E isomeric distribution, preferring the E conformation in polar hydrogen‑bonding solvents and the Z conformation in halogenated solvents. Thioacetanilide serves as a substrate for metabolic desulfurization and aromatic hydroxylation. Thioacetanilide is mainly metabolized via desulfurization and 4‑hydroxylation of the aromatic ring in Rattus norvegicus, and the released sulfur integrates into the total body sulfur pool. Thioacetanilide is well absorbed in rats, and more than 90% of the dose is excreted in urine as conjugated metabolites after oral administration .
    Thioacetanilide
  • HY-14977
    CS-0777-P

    		LPL Receptor Inflammation/Immunology
    CS-0777-P, the phosphorylated form of CS-0777, acts as a potent and selective modulator of the S1P receptor-1 (S1P1). It exhibits approximately 320-fold higher agonist activity for human S1P1 compared to S1P3, with an EC50 of 1.1 nM. In pharmacological studies, CS-0777-P demonstrated significant effects in vitro as an S1P1 and S1P3 agonist, leading to lowered peripheral blood lymphocyte counts and suppressive effects on experimental autoimmune encephalomyelitis (EAE) in rats. Pharmacokinetic studies in rats revealed rapid lymphocyte count reductions following oral administration, making CS-0777 a promising candidate currently undergoing clinical trials for the treatment of multiple sclerosis (MS) .
    CS-0777-P
  • HY-126835
    A924

    		Amino Acid Derivatives Cancer
    A 924 is an amino acid derivative-based, orally active antitumor agent. A 924 is effective in inhibiting ascites tumors in rat models by intraperitoneal injection or oral administration. The LD50 of A 924 in mice is >1.5 g/kg and >4.5 g/kg by intraperitoneal injection or oral administration, respectively. A 924 does not cause teratogenicity or adverse reactions in normal or pregnant mice .
    A924
  • HY-W031110
    2-Methyl-tetrahydro-β-carboline

    2-MTHBC

    		 Drug Metabolite Neurological Disease
    2-Methyl-tetrahydro-β-carboline is a cyclization product of N,N-dimethyltryptamine after oral administration of ayahuasca .
    2-Methyl-tetrahydro-β-carboline
  • HY-W740380
    21-Carboxylic acid triamcinolone acetonide

    		Drug Metabolite Others
    21-Carboxylic acid triamcinolone acetonide is a metabolite produced in the body after oral administration of [14C]-triamcinolone acetonide .
    21-Carboxylic acid triamcinolone acetonide
  • HY-122307
    Sulisatin

    DAN-603

    		 Bacterial Metabolic Disease
    Sulisatin (DAN-603) is an anionic laxative that is hydrolyzed to diphenolic derivatives by bacterial aryl sulfate sulfohydrolases in the colon during oral administration .
    Sulisatin
  • HY-120639
    BMS-663749 lysine

    		HIV Others
    BMS-663749 lysine is a prodrug of an HIV-1 attachment inhibitor with the potential to enhance the delivery of the parent compound following oral administration.
    BMS-663749 lysine
  • HY-135245
    Ezetimibe hydroxy glucuronide

    SCH 488128; Ezetimibe hydroxy β-D-Glucuronide

    		 Drug Metabolite Cardiovascular Disease
    Ezetimibe hydroxy glucuronide (SCH 488128) is a trace metabolite detected in dog and human plasma samples after oral administration of Ezetimibe (HY-17376) .
    Ezetimibe hydroxy glucuronide
  • HY-129579
    Linadryl

    		Histamine Receptor Others
    Linadryl is a compound with antihistamine and other effects. It has a variable effect on gastric acid secretion after oral administration, and its effect is about half that of Diphenhydramine (HY-B0303).
    Linadryl
  • HY-122307A
    Sulisatin disodium

    DAN-603 disodium

    		 Bacterial Metabolic Disease
    Sulisatin (DAN-603) disodium is an anionic diarrhea-promoting compound. During oral administration, Sulisatin disodium is hydrolyzed to diphenolic derivatives by bacterial aryl sulfate sulfohydrolases in the colon .
    Sulisatin disodium
  • HY-169199
    BAY-405

    		MAP4K Cancer
    BAY-405 (compund 38) is a MAP4K1 inhibitor that exhibits nanomolar potency in biochemical and cellular assays and achieves in vivo exposure after oral administration .
    BAY-405
  • HY-102061
    Naronapride dihydrochloride

    ATI 7505 dihydrochloride

    		 Others Others
    Naronapride (dihydrochloride) (ATI 7505 (dihydrochloride)) is a compound that regulates gastrointestinal motility. It is a 5-HT receptor agonist. It is extensively metabolized after oral administration and is mainly excreted through feces. It has certain pharmacokinetic properties.
    Naronapride dihydrochloride
  • HY-19899
    APD-916

    		Histamine Receptor Neurological Disease
    APD-916 is an H3 receptor antagonist. APD-916 shows good pharmacokinetic properties, and oral administration of APD-916 has been shown to enhance wakefulness in various animal models .
    APD-916
  • HY-105919
    Naroparcil

    		Factor Xa Cardiovascular Disease
    Naroparcil is an orally active antithrombotic agent. Naroparcil exhibits antithrombotic effects in rabbit Wessler stasis model with EC50s of 21.9 mg/kg and 36.0 mg/kg after respectively intravenous injection and oral administration .
    Naroparcil
  • HY-149900
    Antiviral agent 33

    		Biochemical Assay Reagents Infection
    Antiviral agent 33 (compound 1c) is a double-stranded DNA (dsDNA) virus inhibitor with IC50 values of 0.0790 and 0.1572 µM for VACV and AdV5, respectively. Antiviral agent 33 also has potential for oral administration .
    Antiviral agent 33
  • HY-147152
    1-Myristoyl-3-chloropropanediol

    		Biochemical Assay Reagents Others
    1-Myristoyl-3-chloropropanediol is a 3-monochloropropanediol (3-MCPD) fatty acid ester. 3-MPCD causes nephropathy and tubular hyperplasia and adenomas by chronic oral administration; also reduces fertility, or provokes infertility in rats and suppresses the immune function .
    1-Myristoyl-3-chloropropanediol
  • HY-105498
    ADD-196022

    		Sodium Channel Neurological Disease
    ADD-196022 is an orally active antiepileptic and anticonvulsant agent. ADD-196022 shows ED50 values of 26.2 mg/kg and 5.79 mg/kg for intraperitoneal injection in mice and orally administration in rats. ADD-196022 can be used for the research of neurological disease .
    ADD-196022
  • HY-162893
    SX29

    		Glycosidase Metabolic Disease
    SX29 is an orally active non-competitive α-glucosidase inhibitor with an IC50 value of 2.12 μM. SX29 exhibits hypoglycemic activity, and oral administration of SX29 can reduce blood glucose levels and improve glucose tolerance in diabetic mice .
    SX29
  • HY-A0234R
    Stepronin (Standard)

    Prostenoglycine (Standard); TTPG (Standard); Tiase (Standard)

    		 Chloride Channel Reference Standards Endocrinology
    Stepronin (Standard) is the analytical standard of Stepronin. This product is intended for research and analytical applications. Stepronin (Prostenoglycine) is an orally active expectorant (inhalation administration is preferable to oral administration). Stepronin inhibits airway secretion in vitro by reducing Cl - secretion from epithelial cells and mucus glycoprotein secretion from submucosal glands .
    Stepronin (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: